Telitacicept Slows Kidney Function Decline in Phase 3
The drug shows an 89% reduction in kidney function decline risk for IgA nephropathy patients in long-term trial results.
Updated on Oct. 22, 2026 in Biotech
Live Poll
Should the government prioritize funding for new clinical trials that target chronic kidney diseases?
Vor Bio reported final two-year results from its Phase 3 TELIGAN trial, demonstrating that telitacicept significantly slowed kidney function decline in adults with IgA nephropathy. The data show a marked reduction in disease progression markers compared to placebo over 104 weeks.
Why it matters
This study validates a dual inhibition approach for managing IgA nephropathy by targeting specific immune pathways to reduce autoantibody production. The results provide clinical evidence for telitacicept as a potential therapeutic option for preventing long-term kidney failure.
The trial recorded an annualized eGFR slope of -0.6 mL/min/1.73 m²/year for the telitacicept group compared to -5.7 mL/min/1.73 m²/year for placebo. Participants also saw a 60.3% decrease in urine protein-to-creatinine ratio and a 47.79% reduction in serum galactose-deficient IgA1.
The players
Vor Bio
A biotechnology company focused on developing targeted therapies, including novel B-cell inhibitors for autoimmune conditions.
The details
Telitacicept functions as a dual inhibitor of BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). By blocking these proteins, the therapy reduces the population of autoreactive B cells—the immune cells responsible for producing damaging autoantibodies that attack kidney tissue. Patients in the study received 240 mg of the drug subcutaneously once weekly for the first 39 weeks and every other week thereafter.
Timeline
May 2026: 39-week study results were published.
June 2026: Telitacicept received conditional approval in China.
October 22, 2026: Final 104-week trial results were presented in Denver.
The Tech Race
This development follows recent conditional approvals for telitacicept and establishes a new benchmark for B-cell modulation in autoimmune kidney disease. Vor Bio is now positioning the drug to compete in global trials for other indications like myasthenia gravis.
For patients with IgA nephropathy, these results suggest a potential new maintenance therapy that may forestall the need for more invasive kidney interventions. While the drug is already conditionally approved in China, global availability remains subject to pending regulatory milestones.
The takeaway
This study confirms that targeting BAFF/APRIL pathways can significantly slow the decline of kidney function in IgA nephropathy patients. Observers should track Vor Bio's upcoming global trial data for myasthenia gravis and Sjögren's disease to gauge the platform's broader efficacy.
Further reading
For broader developments in therapeutic pipelines, visit the Biotech section.
Live Poll
Should the government prioritize funding for new clinical trials that target chronic kidney diseases?
